Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2003
08/14/2003WO2003066055A1 Quinoline derivatives as npy antagonists
08/14/2003WO2003066051A1 Preventive and/or therapeutic agent for cardiac disorder
08/14/2003WO2003066050A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
08/14/2003WO2003066047A1 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
08/14/2003WO2003066045A1 Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ace inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan
08/14/2003WO2003066037A1 Spermidine derivatives for the treatment of chronic neurodegenerative diseases
08/14/2003WO2003066023A1 A stable pharmaceutical formulation comprising torsemide modification ii
08/14/2003WO2003066005A2 Ansamycins having improved pharmacological and biological properties
08/14/2003WO2003066003A2 Anti-pathogen treatements
08/14/2003WO2003065999A2 Proliferated cell lines and uses thereof
08/14/2003WO2003065997A2 Anti-infarction molecules
08/14/2003WO2003065989A2 (oxime)carbamoyl fatty acid amide hydrolase inhibitors
08/14/2003WO2003065988A2 A combination for treating cold and cough
08/14/2003WO2003065987A2 Granzyme b inhibitors
08/14/2003WO2003065984A2 Methods and compositions for treating cardiovascular disease
08/14/2003WO2003065983A2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
08/14/2003WO2003065974A2 Hexa-, hepta-, and octapeptides having antiangiogenic activity
08/14/2003WO2003053941A3 Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
08/14/2003WO2003045437A8 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
08/14/2003WO2003037335A8 5-heteroatom-substituted pyrazoles
08/14/2003WO2003031408A3 Tricyclic compounds useful for modulating lxr
08/14/2003WO2003027232A3 Method for producing biologically active products
08/14/2003WO2003020765A3 Vaccine therapies and prophylactic treatments of atherosclerotic diseases
08/14/2003WO2002101048A3 NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
08/14/2003WO2002064083A3 Synthesis of 3-amino-thalidomide and its enantiomers
08/14/2003WO2002058733B1 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
08/14/2003WO2002058703A3 The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers
08/14/2003WO2002058626A3 Methods and compositions for the identification and treatment of neurodegenerative disorders
08/14/2003WO2002057453A3 Polypetides and nucleic acids encoding same
08/14/2003WO2002051439A3 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
08/14/2003WO2002051438A3 Use of repulsive guidance molecule (rgm) and its modulators
08/14/2003WO2002043807A3 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
08/14/2003WO2002029055A3 Carbohydrate-associated proteins
08/14/2003WO2002016584A3 Process for the preparation of neutrophil inhibitory factor
08/14/2003WO2002015933A3 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
08/14/2003WO2002011714A3 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
08/14/2003WO2001092527A3 Regulators of apoptosis
08/14/2003WO2001090148A3 Neurotransmitter transporters
08/14/2003WO2001077067A3 Solid phase synthesis of lxr ligands
08/14/2003US20030153801 Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
08/14/2003US20030153755 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases
08/14/2003US20030153628 Aldose reductase inhibitors and pharmaceutical compositions
08/14/2003US20030153621 Administering mixtures of 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE) and carriers comprising glycerides or fatty esters as controllers of endothelial growth factors
08/14/2003US20030153613 Hypotensive agents for eye, using an aclurea indole compounds, potassium channel blockers; glaucoma
08/14/2003US20030153610 Substituted oxazolidinones and their in the field of blood coagulation
08/14/2003US20030153606 Antiproliferative agents for treating adipocyte differentiation, cancer, osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease
08/14/2003US20030153605 Enzyme inhibitors of nitric oxide synthase
08/14/2003US20030153604 Anticoagulants
08/14/2003US20030153596 Novel thiourea derivatives and the pharmaceutical compositions containing the same
08/14/2003US20030153588 Such as N-butyl-2-(4-(4-chloro-3-methoxyphenyl)-5-pyridin-4-yl-1H-imidazole-2 -yl)isobutylamide for treatment of neurotraumatic disorders
08/14/2003US20030153587 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
08/14/2003US20030153575 Tetracyclic diketopiperazine compounds as pdev inhibitors
08/14/2003US20030153574 Such as 4-(Benzoxazol-2-yl)-1,4-diazabicyclo(3.2.2)nonane hydrobromide which stimulates nicotinic receptors
08/14/2003US20030153569 Novel pyrazole and pyrazoline substituted compounds
08/14/2003US20030153568 Serine/threonine and tyrosine kinases inhibitors
08/14/2003US20030153566 Adenosine receptor agonist
08/14/2003US20030153564 New oxabispidine compounds useful in the treatment of cardiac arrhythmias
08/14/2003US20030153563 CRF receptor antagonists and methods relating thereto
08/14/2003US20030153559 Treatment of an oxygen and/or energy deficit; a poly(adenosine diphosphate ribose)-polymerase inhibitor; treating autoimmune, neurodegenerative and diseases caused by a toxic effect; viricides
08/14/2003US20030153557 Treating osteoporosis, cardiovascular disorders, restenosis, arteriosclerosis, nephropathies or retinopathies; antitumor and antiinflammatory agents
08/14/2003US20030153553 Quinoline derivatives
08/14/2003US20030153549 Clavulinic acid derivatives; antibiotics
08/14/2003US20030153541 Liver X receptor modulator comprising an oxysterol, lipid regulating HMG-CoA reductase inhibitor, fibric acid derivative, niacin, bile-acid sequestrant, probucol, raloxifene, unsaturated omega-3 fatty acid
08/14/2003US20030153536 Compounds and methods of treating transplant rejection
08/14/2003US20030153525 Identifies differential expression of 1465, 1587, 2146, 2207, 32838, 336 OR 52908 genes in tissues relating to pain sensation relative to their expression in normal or non-painful disease states
08/14/2003US20030153524 Including extracellular matrix production and/or deposition, neovascularization, inflammation, cell proliferation, cell migration, associated with connective tissue growth factor by administering agent that decreases expression of the factor
08/14/2003US20030153523 Screening library of test compounds, each of which is attached to a solid support, with a dye-labeled RNA molecule to form a dye-labeled target RNA:support-attached test compound complex
08/14/2003US20030153510 Novel compounds inhibiting factor xa activity
08/14/2003US20030153506 Anticoagulant therapy; multicompartment kits, synergistic effect using the mixtures
08/14/2003US20030153503 Therapeutic treatment of hypoxia, anemia, and enzyme inhibitors; antihypoxic agents
08/14/2003US20030153063 Polypeptides; membrane proteins for diagonsis, prevention and treatment of cardiovascular disorders
08/14/2003US20030153018 Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710
08/14/2003US20030152973 G-protein coupled receptor org3
08/14/2003US20030152970 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
08/14/2003US20030152947 Methods for detecting and treating the early onset of aging-related conditions
08/14/2003US20030152946 Bh4-fused polypeptides
08/14/2003US20030152654 Ginkgo biloba composition, method to prepare the same and uses thereof
08/14/2003US20030152651 Herbal composition for angina pectoris, method to prepare same and uses thereof
08/14/2003US20030152617 Capsule, tablet with enteric, protective coatings; bioavailability
08/14/2003US20030152615 Enhanced drug delivery in transdermal systems
08/14/2003US20030152614 Enhanced drug delivery in transdermal systems
08/14/2003US20030152613 Steroid on carrier containing pressure sensitive adhesive
08/14/2003US20030152594 Immunology response intensifiers; administering a bacterial lysate
08/14/2003US20030152574 Modulate nucleic acid gene expression
08/14/2003US20030152571 Anti-alphabeta3 humanized monoclonal antibodies
08/14/2003US20030152566 Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases
08/14/2003US20030152520 5-Substituted-2-arylpyridines
08/14/2003CA2776902A1 Salts of valsartan
08/14/2003CA2485064A1 Albumin-fused kunitz domain peptides
08/14/2003CA2476281A1 Pyrimidine compounds
08/14/2003CA2476214A1 Proliferated cell lines and uses thereof
08/14/2003CA2475767A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
08/14/2003CA2475637A1 Quinolinone derivatives for treating cell proliferation related disorders
08/14/2003CA2475539A1 Hiv inhibiting proteins
08/14/2003CA2475382A1 Albumin-fused anti-angiogenesis peptides
08/14/2003CA2475329A1 Truncated aggrecanase molecules
08/14/2003CA2475320A1 Quinoxalinones and their use especially in the treatment of cardiovascular diseases
08/14/2003CA2475277A1 Method for producing recombinant proteins in micro-organisms
08/14/2003CA2475247A1 Anti-pathogen treatments
08/14/2003CA2475209A1 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
1 ... 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 ... 1595